Document Type : Original Article
Department of Biotechnology & Bioinformatics, NIIT University, Neemrana, Rajasthan, India
Department of Biotechnology, Netaji Subhas Institute of Technology, University of Delhi, New Delhi, India
Department of Biotechnology, Noida Institute of Engineering and Technology, Greater Noida, India
Department of Endocrinology, Sawai Man Singh Medical College and Hospital, Jaipur, India
Department of Computer Engineering and Applications, GLA University, Mathura, UP, India
Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China
Introduction: Coronaviruses are significant pathogens of both human and animals and are globally distributed. Out of seven CoVs strains, the most lethal coronavirus strains being portrayed is SARS-CoV-2. It can cause bronchial asthma, and severe pneumonia and acute respiratory disease. Due to its contagion in infants, adults, and immunocompromised patients which further results in making this a deadly disease, thus there is an urgent need to develop effective and safe therapeutics against it.
Materials and Methods: Meta-analysis of publicly available gene expression datasets belonging to SARS-CoV-2, SARS-CoV, MERS-CoV, and HCoV-229E were carried out to identify the potential differentially expressed genes exclusively associated with SARS-CoV-2, and then a network model was developed to decipher significant drug targets, associated pathways and drug candidates which can be repurposed for this infection.
Results: The COVID-19 infection mainly targets immune responses and regulatory processes. A novel role of Relaxin signaling pathway was identified in SARS-CoV-2 infection. Anti-inflammatory, anti-tumor, nutraceutical and anthelmintic agents were found to be good prospective candidates for repurposing against COVID-19.
Conclusions: This theoretical study resulted in the identification of approved drug targets that may have the potential to be repurposed for COVID 19 treatment.